Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dPD-1 hCD19 CAR-T
- Development stage
- Unknown
- Lead developer
- Innovative Cellular Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
dPD-1 hCD19 CAR-T is a chimeric antigen receptor T cell (CAR-T) therapy designed to treat relapsed or refractory non-Hodgkin lymphoma and other B-cell malignancies. This "armored" CAR-T product is engineered to express a humanized anti-CD19 chimeric antigen receptor along with a dominant-negative PD-1 (dPD-1) component. The CD19 targeting enables the modified T cells to recognize and kill malignant B cells expressing CD19. The inclusion of the dominant-negative PD-1 element is intended to block the inhibitory effects of the PD-1/PD-L1 pathway on T cells within the tumor microenvironment, thereby enhancing antitumor activity and persistence of the infused cells. Developed by Innovative Cellular Therapeutics, this therapy represents an advanced approach in immunotherapy by combining direct tumor targeting with checkpoint inhibition in a single cellular product[1].
- Other names
- dPD-1 hCD19 targeted Chimeric Antigen Receptor T CellsdPD1 hCD19 targeted Chimeric Antigen Receptor T CellsdPD 1 hCD19 targeted Chimeric Antigen Receptor T Cells
02
Targets
CD19 (B lymphocyte antigen CD19)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on dPD-1 hCD19 CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dPD-1 hCD19 CAR-T.